Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

Skin Therapy Lett. 2022 Jan;27(1):4-9.

Abstract

Janus kinase inhibitors, also commonly referred to as JAK inhibitors, are a novel drug class that target and block cytokine signaling mediated by the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, thereby regulating immune response and cell growth. Although JAK inhibitors are mainly used for rheumatological conditions such as rheumatoid arthritis, their application in the field of dermatology is actively being investigated. Tofacitinib is US FDA-approved for psoriatic arthritis and showing promise for treating psoriasis. Most recently, regulatory approvals for the US were gained by ruxolitinib as a first-inclass, selective, topical therapy for atopic dermatitis and oral upadacitinib for active psoriatic psoriasis. Additionally, abrocitinib and upadacitinib have demonstrated efficacy in atopic dermatitis and are pending FDA approval for this indication. The therapeutic potential of JAK inhibitors in dermatological conditions such as alopecia areata, psoriasis, atopic dermatitis, vitiligo, and dermatomyositis are showing promising results in clinical trials. Adverse events for JAK inhibitors seem to be similar to that of biologic drugs. Common adverse effects include increased risk of infections and thromboembolic events. Further investigation is needed to not only better understand the safety profile of JAK inhibitors, but also their full utility within the field of dermatology.

Keywords: JAK inhibitors; JAK-STAT; Janus kinase inhibitors; TYK2 inhibitors; abrocitinib; baricitinib; dermatology; ruxolitinib; tofacitinib; tyrosine kinase inhibitors; upadacitinib.

Publication types

  • Review

MeSH terms

  • Alopecia Areata*
  • Dermatology*
  • Humans
  • Janus Kinase Inhibitors* / adverse effects
  • Janus Kinases
  • Vitiligo*

Substances

  • Janus Kinase Inhibitors
  • Janus Kinases